Reilly Financial Advisors Upped Mondelez Intl (MDLZ) Position; VIVUS, Inc. (VVUS) Had 2 Analysts Last Week

April 23, 2018 - By Linda Rogers

Mondelez International, Inc. (NASDAQ:MDLZ) Logo

Reilly Financial Advisors Llc increased Mondelez Intl Inc (MDLZ) stake by 11351.49% reported in 2017Q4 SEC filing. Reilly Financial Advisors Llc acquired 202,170 shares as Mondelez Intl Inc (MDLZ)’s stock declined 5.65%. The Reilly Financial Advisors Llc holds 203,951 shares with $8.73M value, up from 1,781 last quarter. Mondelez Intl Inc now has $59.49B valuation. The stock decreased 2.19% or $0.9 during the last trading session, reaching $40.11. About 12.14M shares traded or 24.84% up from the average. Mondelez International, Inc. (NASDAQ:MDLZ) has declined 6.02% since April 23, 2017 and is downtrending. It has underperformed by 17.57% the S&P500.

Among 2 analysts covering Vivus (NASDAQ:VVUS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vivus had 3 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Buy” rating by WallachBeth Capital given on Thursday, November 5. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, July 31. The stock of VIVUS, Inc. (NASDAQ:VVUS) earned “Hold” rating by Zacks on Wednesday, August 5. See VIVUS, Inc. (NASDAQ:VVUS) latest ratings:

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company has market cap of $40.83 million. The firm offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It currently has negative earnings. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension.

The stock decreased 3.97% or $0.0159 during the last trading session, reaching $0.3851. About 276,671 shares traded. VIVUS, Inc. (NASDAQ:VVUS) has declined 65.45% since April 23, 2017 and is downtrending. It has underperformed by 77.00% the S&P500.

Investors sentiment increased to 0.57 in 2017 Q4. Its up 0.04, from 0.53 in 2017Q3. It increased, as 9 investors sold VIVUS, Inc. shares while 21 reduced holdings. 8 funds opened positions while 9 raised stakes. 25.91 million shares or 20.65% less from 32.65 million shares in 2017Q3 were reported. Goldman Sachs Grp holds 71,428 shares or 0% of its portfolio. Creative Planning holds 0% in VIVUS, Inc. (NASDAQ:VVUS) or 366,706 shares. Dekabank Deutsche Girozentrale, Germany-based fund reported 200 shares. The Illinois-based First L P has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Sg Americas Secs reported 33,995 shares. Massachusetts-based Geode Cap Management Lc has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Acadian Asset Mgmt Llc has invested 0.01% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Jpmorgan Chase & has 0% invested in VIVUS, Inc. (NASDAQ:VVUS) for 2,500 shares. Citadel Advsr Limited Liability reported 40,735 shares. Retail Bank Of America De owns 0% invested in VIVUS, Inc. (NASDAQ:VVUS) for 6,772 shares. 112,000 were reported by California Public Employees Retirement System. 114,123 were reported by Susquehanna Int Group Inc Ltd Liability Partnership. Whittier holds 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS) for 2,500 shares. Fin Architects stated it has 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). The Illinois-based Guggenheim Limited has invested 0% in VIVUS, Inc. (NASDAQ:VVUS).

Investors sentiment increased to 1 in 2017 Q4. Its up 0.16, from 0.84 in 2017Q3. It improved, as 56 investors sold MDLZ shares while 388 reduced holdings. 107 funds opened positions while 338 raised stakes. 1.07 billion shares or 1.13% less from 1.08 billion shares in 2017Q3 were reported. Regions Fin stated it has 307,412 shares. First Advsrs Lp accumulated 746,497 shares. Savant Capital Limited Liability Company has 8,510 shares for 0.08% of their portfolio. Stratos Wealth Prns Ltd holds 26,036 shares. Moreover, Beaumont Financial Prns Ltd Llc has 0.85% invested in Mondelez International, Inc. (NASDAQ:MDLZ) for 170,355 shares. First Manhattan Commerce reported 0.53% in Mondelez International, Inc. (NASDAQ:MDLZ). Logan Management has 28,234 shares for 0.08% of their portfolio. Hbk Invests Lp reported 0.14% stake. Shell Asset reported 119,856 shares. Wealthtrust holds 0% of its portfolio in Mondelez International, Inc. (NASDAQ:MDLZ) for 101 shares. Geode Cap Mgmt Lc has 0.23% invested in Mondelez International, Inc. (NASDAQ:MDLZ). Northeast Investment Management has 0.33% invested in Mondelez International, Inc. (NASDAQ:MDLZ). Stock Yards Comml Bank has 0.12% invested in Mondelez International, Inc. (NASDAQ:MDLZ) for 26,052 shares. Bremer National Association stated it has 7,112 shares or 0.08% of all its holdings. Lord Abbett Ltd Co holds 1.07M shares or 0.13% of its portfolio.

Since February 16, 2018, it had 2 insider buys, and 3 sales for $1.03 billion activity. Shares for $87,800 were bought by BUNCH CHARLES E. MAY PETER W also sold $793.31M worth of Mondelez International, Inc. (NASDAQ:MDLZ) on Tuesday, March 6. Another trade for 6.52M shares valued at $284.87M was made by PELTZ NELSON on Tuesday, February 27. Weber Hubert sold $478,668 worth of stock or 10,931 shares.

Mondelez International, Inc. (NASDAQ:MDLZ) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>